The GRO-SNaPET study: preliminary data on the prediction of lymphonodal status by sentinel lymph node biopsy combined with 18FDG-PET/CT to overcome the current limits of vulvar cancer treatment

Garganese, Giorgia

418
The GRO-SNaPET study: preliminary data on the prediction of lymphonodal status by sentinel lymph node biopsy combined with 18FDG-PET/CT to overcome the current limits of vulvar cancer treatment

Sunday, March 29, 2015: 7:00 AM

Salon C-D (Hilton Chicago)

G. Garganese, S. M. Fragomeni, V. Rufini, G. Perotti, L. Zagaria, A. Collarino, M. T. Evangelista, A. Naldini, C. Rossitto, A. Giordano and G. Scambia
Catholic University of the Sacred Heart, Rome, Italy

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

418
The GRO-SNaPET study: preliminary data on the prediction of lymphonodal status by sentinel lymph node biopsy combined with 18FDG-PET/CT to overcome the current limits of vulvar cancer treatment

418 The GRO-SNaPET study: preliminary data on the prediction of lymphonodal status by sentinel lymph node biopsy combined with 18FDG-PET/CT to overcome the current limits of vulvar cancer treatment

418
The GRO-SNaPET study: preliminary data on the prediction of lymphonodal status by sentinel lymph node biopsy combined with 18FDG-PET/CT to overcome the current limits of vulvar cancer treatment